Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Kenya - engleză - Pharmacy and Poisons Board

syner-med pharmaceuticals (k) ltd gayatri house, icd road, off mombasa road, p.o - ceftazidime pentahydrate usp - powder for injection - ceftazidime pentahydrate usp eq. to ceftazidime 1… - beta-lactamantibacterials: third-generation

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - avibactam sodium; ceftazidime pentahydrate -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - ceftazidime pentahydrate -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - ceftazidime pentahydrate -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - avibactam sodium, quantity: 543.5 mg (equivalent: avibactam, qty 500 mg); ceftazidime pentahydrate, quantity: 2329.7 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - zavicefta is indicated for the treatment of the following infections in adults (see sections 4.4 special warnings and precautions for use and 5.1 pharmacodynamic properties):,? complicated intra-abdominal infection (ciai) in combination with metronidazole. ? complicated urinary tract infection (cuti) including pyelonephritis.,? hospital-acquired pneumonia (hap) including ventilator associated pneumonia (vap).,zavicefta is indicated for the treatment of the following infections in infants and paediatric patients (greater than or equal to 3 months to < 18 years) (see sections 4.4 special warnings and precautions for use and 5.1 pharmacodynamic properties):,? complicated intra-abdominal infection (ciai) in combination with metronidazole. ? complicated urinary tract infection (cuti) including pyelonephritis.,consideration should be given to official guidance on the appropriate use of antibacterial agents.,to reduce the development of drug-resistant bacteria and maintain the effectiveness of zavicefta and other antibiotics, zavicefta should be used in combination with an antibacterial agent(s) active against gram-positive and/or anaerobic pathogens when these are known or suspected to be contributing to the infectious process.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate -

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime   excipient: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: · severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftazidime pentahydrate 2.328 g equivalent to ceftazidime 2 g;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to ceftazidime 2 g   excipient: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: · severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter s